Study of the tolerability and therapeutic effectiveness of the veterinary drug «Butamax 200» when administered intravenously in the complex therapy of maternity paresis of cows
Authors:   Agricultural and Technological Institute of RUDN named after Patrice Lumumba, Moscow, Russia, Rogov Roman V. , Kulikov Evgeniy V. ,   Agricultural and Technological Institute of RUDN named after Patrice Lumumba, Moscow, Russia, Petrov Alexander K. ,   Agricultural and Technological Institute of RUDN named after Patrice Lumumba, Moscow, Russia, Babichev Nikolay V. ,   Agricultural and Technological Institute of RUDN named after Patrice Lumumba, Moscow, Russia, Myachina Margarita V. ,   Agricultural and Technological Institute of RUDN named after Patrice Lumumba, Moscow, Russia, Shepeleva Kristina V. ,   Agricultural and Technological Institute of RUDN named after Patrice Lumumba, Moscow, Russia, Muradyan Zhora Yu. ,   Moscow State Academy of Veterinary Medicine and Biotechnology – MVA by K. I. Skryabin”, Moscow, Russia, Petrova Tatyana N. ,   Moscow State Academy of Veterinary Medicine and Biotechnology – MVA by K. I. Skryabin”, Moscow, Russia, Titov Alexander V. ,   Reprovet LLC, Moscow region, Russia
Published: September 2024

The tolerability and therapeutic effectiveness of the veterinary drug Butamax 200 developed by REPROVET LLC was carried out in the conditions of the MTF Babaevo LLC, Vladimir region, Sobinsky district, village. Babaevo. In order to study side effects and complications as a result of using the drug «Butamax-200» to lactating cows, a group of healthy animals was formed (n=3). The experiment involved cows of the blackand- white (Holsteinized) breed weighing 550–600 kg with a milk yield of 7–8 thousand/head. Animals were treated with the drug for 3 days at a dose three times higher than the therapeutic dose (3 ml per 20 kg of live weight). To assess the therapeutic effectiveness of Butamax 200, taking into account pairs of analogues, three groups of animals of 8 animals each, one experimental and two control, were formed. New cows of the black-and-white (Holsteinized) breed weighing 550–600 kg with a milk yield of 7–8 thousand/year with postpartum complications (maternity paresis) were taken into the experiment. As a result of the intravenous use of Butamax-200 in complex therapy for maternity paresis, animals rose within an hour, TPD normalized, appetite, active chewing and rumination appeared. The animals became active, their general condition improved. No additional use of the standard treatment protocol was required, unlike the comparison drug group. Analysis of the TCA blood of experimental animals showed that as a result of the therapy, there is a decrease in leukocytes, as well as band and segmented neutrophils to the physiological norm, and an increase in the number of lymphocytes. The most pronounced therapeutic effect was noted in experimental group I, thus there was a decrease in leukocytes by 17,9 %. After the therapy, an increase in the amount of hemoglobin to the physiological norm was noted in all experimental groups. The most significant results were obtained in experimental group I, where Butamax-200 was used; as a result, hemoglobin increased by 8,2 % compared to the comparison drug. Therapy with Butamax- 200 has a positive effect on mineral and protein metabolism in the body, which is reflected in the biochemical picture of the blood. Thus, the calcium level was higher than in the comparison drug group «Butofan®» by 18,5 %, and total protein by 8,4 % respectively.